Shannon Marie Vandriel

Shannon Marie Vandriel

Auto-generated profile, based on publicly available information

Shannon Marie Vandriel

Division of Gastroenterology, Hepatology and Nutrition The Hospital for Sick Children and the University of Toronto Toronto Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Hepatology
Verified
Journal Article
Open access
SVShannon M. Vandriel
Shannon M. Vandriel
LLLi‐Ting Li
Li‐Ting Li
HSHuiyu She
Huiyu She
JWJian‐She Wang
Jian‐She Wang
MGMelissa A. Gilbert
Melissa A. Gilbert
BKBinita M. Kamath
Binita M. Kamath
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event‐free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18‐year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver‐related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dl had a 4.1‐fold (95% confidence interval [CI], 1.6–10.8), and those ≥10.0 mg/dl had an 8.0‐fold (95% CI, 3.4–18.4) increased risk of developing CEPH compared with those <5.0 mg/dl. Median TB levels between ≥5.0 and 10.0 mg/dl were associated with a 4.8 (95% CI, 2.4–9.7) and 15.6 (95% CI, 8.7–28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to ≥5.0 mg/dl, with 79% reaching adulthood with native liver (p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision‐making and in the evaluation of therapies.

24 February 2017 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
APArpita Parmar
Arpita Parmar
SVShannon Marie Vandriel
Shannon Marie Vandriel
VNVicky Lee Ng
Vicky Lee Ng

6 June 2022 in Liver International
Verified
Journal Article
Closed access
SASaleh A Alqahtani
Saleh A Alqahtani
RCRose Chami
Rose Chami
DADua Abuquteish
Dua Abuquteish
SVShannon M. Vandriel
Shannon M. Vandriel
CYCharesse Yap
Charesse Yap
ISIram Siddiqui
Iram Siddiqui

31 July 2025 in Liver International
Verified
Journal Article
Open access
SVShannon M. Vandriel
Shannon M. Vandriel
LLLi‐Ting Li
Li‐Ting Li
HSHuiyu She
Huiyu She
JWJianshe Wang
Jianshe Wang
KLKathleen M. Loomes
Kathleen M. Loomes
TGThe Global ALagille Alliance (GALA) Study Group
The Global ALagille Alliance (GALA) Study Group
Background & Aims: Alagille syndrome (ALGS) is a rare, autosomal dominant disorder with high phenotypic heterogeneity. Disease‐causing variants are primarily identified in Jagged1 ( JAG1 ), with fewer reported in NOTCH2 . JAG1 variants cause disease through a mechanism of haploinsufficiency, but the mechanism for NOTCH2 variants is not completely understood, making classification of variants more challenging. Using a large, international patient cohort acquired through the Global ALagille Alliance (GALA) study, we sought to improve classification of NOTCH2 variants and study phenotypic differences between NOTCH2‐ and JAG1‐ related disease. Methods: Clinical and molecular data from 952 individuals with ALGS in GALA were analysed and disease features compared between those with JAG1 ( n = 902) and NOTCH2 ( n = 34) variants. Previously reported and newly identified NOTCH2 variants were reinterpreted based on disease‐specific modifications to the American College of Medical Genetics and Genomics (ACMG) guidelines. The Kaplan–Meier method was utilised to assess native liver survival (NLS) and overall survival (OS) and gene comparisons were made with the log‐rank test. Results: Thirty NOTCH2 variants, including 18 novel variants, were identified and classified in our GALA cohort. Phenotypic analyses revealed a significantly lower incidence of characteristic facies, posterior embryotoxon, cardiac involvement and butterfly vertebrae in individuals with NOTCH2 variants compared to those with JAG1 variants ( p < 0.001). No differences were identified in NLS or OS. Review of 61 previously reported NOTCH2 variants resulted in the re‐classification of 19 likely pathogenic or pathogenic to VOUS (31.1%) with less than half retaining their originally published classification (34.4%; n = 21). Conclusions: We report on a large global study on NOTCH2 genetics and phenotype, which increases the number of reported NOTCH2 variants by 30%. All variants were reclassified using current guidelines, and comparison of the JAG1 and NOTCH2 cohorts demonstrates clear phenotypic divergence between these groups. These data suggest that reliance on classical clinical phenotyping may miss patients with NOTCH2‐ related disease and supports an inclusive approach to genetic testing.

17 January 2025 in Liver International
Verified
Journal Article
Open access
GHGideon Hirschfield
Gideon Hirschfield
SVShannon M. Vandriel
Shannon M. Vandriel
DMDouglas B. Mogul
Douglas B. Mogul
MBMarshall Baek
Marshall Baek
PVPamela Vig
Pamela Vig
BKBinita M. Kamath
Binita M. Kamath
Background: Alagille syndrome (ALGS) is a multisystem cholestatic disorder. Maralixibat is approved for the treatment of cholestatic pruritus in ALGS with limited data in adults.Methods: Participants were included if they received ≥ 2 doses of maralixibat at age ≥ 16 years in one of the three previously published maralixibat ALGS clinical trials.Results: Eleven initiated treatment < 16 years old (median age, 13.0) with a median follow‐up of 4.1 years. Three participants began maralixibat at ≥ 16 years old, with a median follow‐up of 3.8 years. Participants starting maralixibat at age < 16 had minimal‐to‐no itch (change from baseline [CFB]: −1.8; p = 0.002) persisting throughout the study. Serum bile acids (sBA) decreased (CFB: 29 μmol/L; p = 0.03), persisting throughout the study. Participants starting maralixibat ≥ 16 years old had pruritus improvements (CFB: −2.8, −0.6, −1.0). One had a large decrease in sBA (CFB: −112 μmol/L), and two had small increases (CFB: 8, 11 μmol/L). Maralixibat was well tolerated.Conclusion: Participants receiving maralixibat in adolescence demonstrated improvements in pruritus and sBA, which persisted through young adulthood.

18 November 2025 in Liver International
Verified
Journal Article
Open access
CPCarla Fiorella Murillo Perez
Carla Fiorella Murillo Perez
SVShannon M. Vandriel
Shannon M. Vandriel
EGEmmanuel M. Gonzales
Emmanuel M. Gonzales
JWJianshe Wang
Jianshe Wang
LLLi‐Ting Li
Li‐Ting Li
BKBinita M. Kamath
Binita M. Kamath
Background and Aim: Alagille syndrome (ALGS) is a rare disorder characterised by cholestasis and extrahepatic manifestations. Given the current era of ileal bile acid transporter (IBAT) inhibitor therapies that reduce serum bile acid (SBA) levels, we evaluated whether SBA predicts liver disease outcomes in ALGS. Methods: Patients were ascertained from the G lobal AL agille A lliance (GALA) cohort. A prognostic threshold of SBA 102 μmol/L was assessed as a time‐dependent covariate in Cox regression analyses for native liver survival (NLS) and event‐free survival (EFS), while adjusting for total bilirubin (TB) levels. Results: 570 GALA patients were included (348 [61%] male). There was a moderate positive correlation between SBA and TB (Pearson correlation = 0.47, p < 0.001). SBA below 102 μmol/L was a significant predictor of outcomes (NLS: HR = 3.78, 95% CI 2.39–5.99, p < 0.001; EFS: HR = 3.44, 95% CI 2.35–5.04, p < 0.001). SBA remained a significant predictor for improved EFS after adjusting for TB clearance at 1 year (TB < 2 mg/dL; HR = 2.00, 95% CI 1.10–3.65, p = 0.02). Median SBA in the first year of life above 102 μmol/L, predicted lower NLS (67.2% vs. 83.5% at 7 years p = 0.05) and EFS (63.4% vs. 80.9% at 7 years, p = 0.02). Conclusion: Lower SBA in children with ALGS liver disease predicts improved NLS and EFS. SBA is also associated with NLS in children with ALGS who clear their bilirubin, that is, those with anicteric cholestasis. Although the patients studied here did not receive IBAT inhibition, these data suggest that lowering SBA may improve important clinical outcomes.